United States · FDA National Drug Code directory
WAYRILZ
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 58468-0251_aa3b7d8a-0e0d-481b-bd36-4befaceba422
- Product NDC
- 58468-0251
- Form
- TABLET, FILM COATED
- Composition / generic term
- rilzabrutinib
- Labeler
- Genzyme Corporation
- Marketing category
- NDA
- Marketing start / end (source format)
- 20250829
- Source listing expiry
- 20261231
Source-listed ingredients
- RILZABRUTINIB — 400 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 2 BLISTER PACK in 1 CARTON (58468-0251-5) / 28 TABLET, FILM COATED in 1 BLISTER PACK (58468-0251-0) · 58468-0251-5
- 1 BOTTLE in 1 CARTON (58468-0251-6) / 60 TABLET, FILM COATED in 1 BOTTLE · 58468-0251-6
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →